Mattel Unveils First-of-its-Kind, CarbonNeutral® Matchbox® Tesla Roadster Die-cast Vehicle Made from 99% Recycled Materials to Serve as Brand Blueprint
15.4.2021 07:01:00 EEST | Business Wire | Press release
Today, Mattel, Inc. (NASDAQ: MAT) announced Drive Toward a Better Future, its product roadmap to make all Matchbox die-cast cars, playsets and packaging with 100% recycled, recyclable or bio-based plastic by 2030. This is in line with Mattel’s goal to achieve 100% recycled, recyclable or bio-based plastic materials across all its products and packaging by 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414006005/en/
Mattel is unveiling the Matchbox Tesla Roadster, its first die-cast vehicle made from 99% recycled materials and certified CarbonNeutral®*. The Matchbox Tesla Roadster will be available starting in 2022. (Photo: Business Wire)
To illustrate these principles, Mattel is unveiling the Matchbox Tesla Roadster, its first die-cast vehicle made from 99% recycled materials and certified CarbonNeutral®*. The Matchbox Tesla Roadster will be available starting in 2022.
The reimagined broader Matchbox brand includes new product lines and packaging that feature:
- More environmentally friendly and innovative materials across vehicles, playsets and packaging
- Enhanced consumer recycling through product design and packaging labeling
- An overall eco-friendly themed approach to play, with more e-vehicle product offerings and e-vehicle chargers in fuel station playsets
“Since the inception of the modern-day die-cast car nearly 70 years ago, Matchbox has been using design and innovation to connect kids with the real world around them through play,” said Roberto Stanichi, Global Head of Vehicles at Mattel. “Matchbox is committing to using 100% recycled, recyclable or bio-based plastic materials to do our part in addressing the environmental issues we face today, and empower the next generation of Matchbox fans to help steer us towards a sustainable future.”
Fans will see the Matchbox commitment realized through products with zero-plastic packaging, using Forest Stewardship Council® (FSC)-certified content in the paper and wood fiber materials, on shelf starting now. The first die-cast vehicle to have zero-plastic packaging includes the popular Matchbox Power Grabs® assortment featuring a variety of licensed and original 1:64 scale Matchbox die-cast vehicles, while an EV-themed five-pack is now available with a paper foam inner tray.
In addition to introducing zero-plastic packaging, Matchbox is promoting proper recycling and waste recovery. Designed for recyclability with recyclable parts, electronics in playsets are consolidated into a single, easily removable module to help make the local e-waste recycling process easier. How2Recycle labeling guides consumers on the proper disposal of packaging materials. Matchbox is also exploring ways to reduce energy use, carbon emissions and waste in operations, while delivering the same standard of excellence across Matchbox products.
For more information on Matchbox sustainability commitments, you can visit: http://www.matchbox.com/sustainability/
*The Matchbox Tesla Roadsters have been certified CarbonNeutral® by Natural Capital Partners with carbon offset credits going towards preserving grasslands in Colorado and Montana.
About Mattel
Mattel is a leading global toy company and owner of one of the strongest catalogs of children’s and family entertainment franchises in the world. We create innovative products and experiences that inspire, entertain and develop children through play. We engage consumers through our portfolio of iconic brands, including Barbie®, Hot Wheels®, Fisher-Price®, American Girl®, Thomas & Friends®, UNO® and MEGA®, as well as other popular intellectual properties that we own or license in partnership with global entertainment companies. Our offerings include film and television content, gaming, music and live events. We operate in 35 locations and our products are available in more than 150 countries in collaboration with the world’s leading retail and ecommerce companies. Since its founding in 1945, Mattel is proud to be a trusted partner in empowering children to explore the wonder of childhood and reach their full potential.
MAT-W MAT-SU
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414006005/en/
Contact information
Mattel Global Brand Communications
Scott Shaffstall
+1.949.285.6315
Scott.Shaffstall@Mattel.com
Weber Shandwick Worldwide
Austen Hohendorf
+1.212.546.7822
Ahohendorf@webershandwick.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom